Genmab reports Phase 2 data showing median overall survival above two years for petosemtamab plus pembrolizumab in first-line recurrent or metastatic PD-L1+ head and neck cancer; Phase 3 topline data expected later this year

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.